EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study

Yiyu Guo, Xinyu Xu, Tian Wang, Ying Liu, Dayong Gu, Ying Fang, Qiang Wang, Haifeng Shi, Daguang Wu, Zhi Zhang, Guoren Zhou, Jinjun Ye

International Immunopharmacology · 2024-09 · 138 · 112558

DOI: 10.1016/j.intimp.2024.112558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Yiyu Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Rese…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Esophageal Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bethune Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study aims to analyze the efficacy and safety of neoadjuvant programmed cell death-1 (PD-1) blockade plus chemotherapy in real-world applications. Additionally, we report survival outcomes with a median follow-up of 40.1 months. METHODS: From January 2018 to October 2022, we retrospectively recruited patients with esophageal squamous cell carcinoma (ESCC) who underwent surgery after receiving PD-1 blockade (immunotherapy) plus chemotherapy at Jiangsu Cancer Hospital. RESULTS: A total of 132 eligible ESCC patients were included, and R0 resection was achieved in 131 cases (99.2 %). A complete pathological response rate (ypT0N0) was observed in 32 patients (24.2 %), and the objective response rate was 59.1 %. The most common grade 3-4 treatment-related adverse events (TRAEs) were leukopenia (18.2 %) and neutropenia (15.9 %). Three cases (2.3 %) of grade 3 immune-related AEs were observed, including increased ALT (0.8 %), rash (0.8 %), and encephalitis (0.8 %). The 1-year disease-free survival (DFS) and overall survival (OS) rates were 68.2 % and 89.4 %, respectively, and the 2-year DFS and OS rates were 55.1 % and 78.6 %, respectively. The pathological responses of 103 cases (94.5 % of 109) of the index lymph node (ILN) were categorized as the worst regression subgroup. In these cases, using the pathological response of the ILN to indicate the status of other lymph nodes would not result to a missed therapeutic lymph node dissection. CONCLUSIONS: Neoadjuvant immunotherapy plus chemotherapy is safe and effective for ESCC, with observable survival benefits. The pathological response of the ILN after neoadjuvant therapy may have important value in guiding therapeutic lymph node dissection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaNeoadjuvant TherapyEsophageal NeoplasmsHumansMaleMiddle AgedFemaleRetrospective StudiesAgedAdultImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeImmune Checkpoint InhibitorsEsophagectomyProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Esophageal squamous cell carcinomaImmunotherapy and chemotherapyIndex lymph nodeNeoadjuvantSurvival outcomes

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Department of Pathology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
  • Department of Oncology, Affiliated Jiangyan Hospital of Nanjing University of Chinese Medicine, Taizhou, China.
  • Department of Oncology, Sheyang People's Hospital, Yancheng, China.

Förderung

  • Bethune Charitable Foundation

Zitieren

APA

Guo, Y., Xu, X., Wang, T., Liu, Y., Gu, D., Fang, Y., Wang, Q., Shi, H., Wu, D., Zhang, Z., Zhou, G., & Ye, J. (2024). Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study. International Immunopharmacology, 138, 112558. https://doi.org/10.1016/j.intimp.2024.112558

Vancouver

Guo Y, Xu X, Wang T, Liu Y, Gu D, Fang Y, et al. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study. International Immunopharmacology. 2024;138:112558. doi:10.1016/j.intimp.2024.112558

BibTeX
@article{Guo2024,
  author = {Guo, Yiyu and Xu, Xinyu and Wang, Tian and Liu, Ying and Gu, Dayong and Fang, Ying and Wang, Qiang and Shi, Haifeng and Wu, Daguang and Zhang, Zhi and Zhou, Guoren and Ye, Jinjun},
  title = {Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {138},
  pages = {112558},
  doi = {10.1016/j.intimp.2024.112558}
}
Kostenlos starten →